Therapeutic Advances in Oncology

Around 77 new oncology drugs were approved by the FDA in the past five years; however, most cancers remain untreated. Small molecules and antibodies are dominant therapeutic modalities in oncology. Antibody-drug conjugates, bispecific antibodies, peptides, cell, and gene-therapies are emerging to ad...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-02, Vol.22 (4), p.2008
Main Authors: Liu, Jinsha, Pandya, Priyanka, Afshar, Sepideh
Format: Article
Language:English
Subjects:
Antibodies
Antibodies, Monoclonal - therapeutic use
Antigens
Biological products
Bispecific antibodies
Breast cancer
Cancer therapies
Cell- and Tissue-Based Therapy - methods
CRISPR
Deoxyribonucleic acid
DNA
Drugs
FDA approval
Gene therapy
Genetic engineering
Genetic Therapy - methods
Humans
Immunoconjugates - therapeutic use
Immunotherapy
Immunotherapy - methods
Immunotherapy - statistics & numerical data
Immunotherapy - trends
Lung cancer
Lymphocytes
Lymphoma
Medical Oncology - methods
Medical Oncology - statistics & numerical data
Medical Oncology - trends
Molecular Targeted Therapy - methods
Molecular Targeted Therapy - statistics & numerical data
Molecular Targeted Therapy - trends
Molecular weight
Multiple myeloma
Neoplasms - classification
Neoplasms - therapy
New technology
Oncology
Peptides
Prostate cancer
Proteins
Review
Small Molecule Libraries - therapeutic use
T cell receptors
Transplants & implants
Tumors
Vaccines
Vectors (Biology)
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Around 77 new oncology drugs were approved by the FDA in the past five years; however, most cancers remain untreated. Small molecules and antibodies are dominant therapeutic modalities in oncology. Antibody-drug conjugates, bispecific antibodies, peptides, cell, and gene-therapies are emerging to address the unmet patient need. Advancement in the discovery and development platforms, identification of novel targets, and emergence of new technologies have greatly expanded the treatment options for patients. Here, we provide an overview of various therapeutic modalities and the current treatment options in oncology, and an in-depth discussion of the therapeutics in the preclinical stage for the treatment of breast cancer, lung cancer, and multiple myeloma.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms22042008